ASLN vs. PULM, BFRI, AIMD, IBIO, HILS, VCNX, TENX, PCSA, KTTA, and SHPH
Should you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Pulmatrix (PULM), Biofrontera (BFRI), Ainos (AIMD), iBio (IBIO), Hillstream BioPharma (HILS), Vaccinex (VCNX), Tenax Therapeutics (TENX), Processa Pharmaceuticals (PCSA), Pasithea Therapeutics (KTTA), and Shuttle Pharmaceuticals (SHPH). These companies are all part of the "pharmaceutical preparations" industry.
ASLAN Pharmaceuticals (NASDAQ:ASLN) and Pulmatrix (NASDAQ:PULM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership.
ASLAN Pharmaceuticals received 4 more outperform votes than Pulmatrix when rated by MarketBeat users. Likewise, 63.49% of users gave ASLAN Pharmaceuticals an outperform vote while only 52.13% of users gave Pulmatrix an outperform vote.
58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 3.6% of Pulmatrix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
ASLAN Pharmaceuticals has a net margin of 0.00% compared to Pulmatrix's net margin of -75.73%. Pulmatrix's return on equity of -44.05% beat ASLAN Pharmaceuticals' return on equity.
Pulmatrix has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Pulmatrix is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
ASLAN Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Pulmatrix has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.
In the previous week, Pulmatrix had 6 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 11 mentions for Pulmatrix and 5 mentions for ASLAN Pharmaceuticals. Pulmatrix's average media sentiment score of 0.11 beat ASLAN Pharmaceuticals' score of 0.06 indicating that Pulmatrix is being referred to more favorably in the news media.
ASLAN Pharmaceuticals currently has a consensus price target of $11.33, indicating a potential upside of 2,733.33%. Pulmatrix has a consensus price target of $10.00, indicating a potential upside of 446.45%. Given ASLAN Pharmaceuticals' higher possible upside, research analysts plainly believe ASLAN Pharmaceuticals is more favorable than Pulmatrix.
Summary
ASLAN Pharmaceuticals beats Pulmatrix on 10 of the 17 factors compared between the two stocks.
Get ASLAN Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ASLAN Pharmaceuticals Competitors List
Related Companies and Tools
